- List
- By Topic
- On Map
- Search Details

ugt1a1 | Recruiting, Not yet recruiting, Available Studies | Interventional Studies | colorectal cancer | irinotecan
Need help? See RSS Feeds
Choose a feed type:

ugt1a1 | Recruiting, Not yet recruiting, Available Studies | Interventional Studies | colorectal cancer | irinotecan (7 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03329183 | Recruiting | High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28 |
|
|
Interventional | Phase 2 |
|
Other |
|
|
90 | All | 18 Years and older (Adult, Senior) | NCT03329183 | HFSFF | November 2017 | June 2018 | November 2020 | November 1, 2017 | November 1, 2017 |
|
||
2 | NCT01963182 | Recruiting | Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
47 | All | 18 Years and older (Adult, Senior) | NCT01963182 | 2013-001275-21 | IriGen | October 2013 | June 2019 | December 2019 | October 16, 2013 | December 29, 2017 |
|
|
3 | NCT01639326 | Recruiting | Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1 |
|
|
Interventional | Phase 2 |
|
Other |
|
|
96 | All | 18 Years to 75 Years (Adult, Senior) | NCT01639326 | IIBSP-IRI-2011-134 | FOLFIRI-AD | July 2012 | July 2018 | September 2018 | July 12, 2012 | May 7, 2015 |
|
|
4 | NCT02256800 | Recruiting | Prospective Analysis of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Combined With FOLFIRI as the First-line Setting |
|
|
Interventional | Not Applicable |
|
Other |
|
|
320 | All | 20 Years to 80 Years (Adult, Senior) | NCT02256800 | KMUHIRB-20130020 | August 13, 2013 | December 2018 | December 31, 2018 | October 6, 2014 | March 8, 2018 |
|
||
5 | NCT02138617 | Recruiting | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
100 | All | 18 Years and older (Adult, Senior) | NCT02138617 | LCCC 1317 | May 2014 | May 2021 | May 2022 | May 14, 2014 | January 30, 2018 |
|
||
6 | NCT01802645 | Recruiting | Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases |
|
|
Interventional | Phase 2 |
|
Other |
|
|
256 | All | 18 Years and older (Adult, Senior) | NCT01802645 | TUD-CELIM2-050 2011-003288-31 |
CELIM2 | February 2013 | July 2017 | July 2020 | March 1, 2013 | September 26, 2014 |
|
|
7 | NCT02605265 | Recruiting | Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 |
|
|
Interventional | Phase 3 |
|
Other |
|
|
360 | All | 18 Years to 75 Years (Adult, Senior) | NCT02605265 | FDRT-R005 | CinClare | October 2015 | December 2017 | December 2020 | November 16, 2015 | December 7, 2016 |
|
† Study has passed its completion date and status has not been verified in more than two years.